OncUpdates

Latest oncology insights for medical professionals and patients| Curating the latest in research, trials & treatment advances| Own Views| Not medical advice

[OncUpdates @OncUpdates]

⭐️ Ep. 2 | #ESMO26 #HERIZON-GEA-01: Role of tislelizumab in 1L HER2+ mGEA

🎙️ @KlempnerSam & @ShrutiPatelMD
✅ Triplet mOS 27 mo vs 22.9 mo (doublet)
✅ ~8.3% higher 3-yr OS
✅ Consistent trend across PD-L1 TAP

#GIOnc #HER2 #OncTwitter #gicsm #MedTwitter

�� Full discussion 👇
https://t.co/qSd5nFvFMt

[OncUpdates @OncUpdates]

🚨Top 10+ Key Studies Presented at #ESMO26 from @OncBrothers

👉Check out this list of studies that are changing/reinforcing current standard of care!

🤔What other studies do you have highlighted on your list?

#OncTwitter #MedTwitter #ESMO #MedX #bcsm #lcsm #gucsm #gicsm

[OncUpdates @OncUpdates]

🚨 #ESMO26 | INTerpath-001: Personalized mRNA neoantigen vaccine (intismeran) + pembrolizumab vs placebo + pembrolizumab in resected stage IIB–IV melanoma 💉

✅ 2-yr RFS: 82.2% vs 70.0%
✅ 2-yr DMFS: 88.5% vs 80.2%
⚠️OS immature

#Melanoma #OncTwitter #medX #MedTwitter

[Dr Amol Akhade @SuyogCancer]

#ESMO26: 4 talking points .
1️⃣ A Presidential LBA leaked to the press in full >24 hours before presentation.
2️⃣ 5 of 12 Presidential LBAs featured China-origin molecules. Is oncology’s centre of gravity shifting east? 🇨🇳
3️⃣ The most anticipated trial didn’t get the biggest applause.
4️⃣ Three Presidential Symposia. Zero audience Q&As . @myESMO

See u at next esmo conference - hopefully in person 🙂

[Nicholas Hornstein @GIMedOnc]

So happy to have the @OncBrothers around so I can try to stay on-top of things outside of GI Oncology. Ya'll fill such a critical role for the field.

[OncUpdates @OncUpdates]

⭐️ #ESMO26 | #HERIZON-GEA-01: OS benefit with zanidatamab regimens in 1L HER2+ mGEA
🎙️ @KlempnerSam & @ShrutiPatelMD
✅ mOS: 22.9 vs 19.6 mo (HR 0.76) zani+chemo vs tras+chemo
✅ Triplet mOS: 27 mo

#GIOnc #HER2 #OncTwitter #gism

🎥 Full discussion 👇
https://t.co/GzsAA0Hhx4

[OncUpdates @OncUpdates]

🚨Top 10+ Key Studies Presented at #ESMO26 from @OncBrothers

👉Check out this list of studies that are changing/reinforcing current standard of care!

🤔What other studies do you have highlighted on your list?

#OncTwitter #MedTwitter #ESMO #MedX #bcsm #lcsm #gucsm #gicsm

[Oncology Brothers @OncBrothers]

We are all done with #ESMO26! 10+ studies that were on our radar and the updated data around them.

Out in the community settings, it’s tough to keep up with all that is happening here in the world of cancer (and this was just ONE conference). Really appreciate you all sharing the data and importantly your take around this: @OncoAlert @weoncologists @DrChoueiri @StephenVLiu @SuyogCancer @dr_yakupergun @drsarahsam @PTarantinoMD @GIMedOnc @BijoyTelivala @RenoHemonc @nlindenberg @jryckman3 @ErikaHamilton9 @myESMO @LorenzaRimassa 🙏🏽🙏🏽

[OncUpdates @OncUpdates]

🫁Targeting EGFR exon 20 ins #NSCLC | #WCLC26 updates

👉@ElaineShumMD+Dr. Bazhenova discuss sunvozertinib, amivantamab, & zipalertinib data + practical considerations!
#LCSM #EGFR #OncTwitter #LungCancer #MedEd #MedTwitter @nyulangone @UCSDHealth #MedX

https://t.co/xK901dLsC7

[Oncology Brothers @OncBrothers]

Day 4 (Presidential III) #ESMO26 highlights:

1. ARTEMIS-011: Risvutatug rezetecan (B7-H3 ADC) in osteosarcoma

2. MOIO: ⬇️ frequency IO in responders

3. TroFuse-005: Sac-TMT in ndometrial Ca

4. KEYNOTE-C93: Pembro mono in 1L dMMR Endometrial Ca

#OncTwitter @myESMO

1/5

[Paolo Tarantino @PTarantinoMD]

For the first time, ADCs deliver a statistically positive truck test in sarcomas! 🛻

[OncUpdates @OncUpdates]

⭐️ #ESMO26 | #HERIZON-GEA-01: OS benefit with zanidatamab regimens in 1L HER2+ mGEA
🎙️ @KlempnerSam & @ShrutiPatelMD
✅ mOS: 22.9 vs 19.6 mo (HR 0.76) zani+chemo vs tras+chemo
✅ Triplet mOS: 27 mo

#GIOnc #HER2 #OncTwitter #gism

🎥 Full discussion 👇
https://t.co/GzsAA0Hhx4

[OncUpdates @OncUpdates]

⭐️Inavolisib data, eligibility & side effects from #INAVO120

🎙️ @KalinskyKevin discusses Inavolisib with @OncBrothers

🎥Watch the full discussion 👇
https://t.co/7aiHustpb5

#OncTwitter #BreastCancer #PIK3CA #Inavolisib #bcsm

[Oncology Brothers @OncBrothers]

1. Krascendo-1: PhIII Divarasib vs sotorasib/adagrasib in prev-treated KRAS G12C NSCLC (n=338):

- mPFS 9.8 vs 5.7mos (HR 0.58)
- mOS 17.7 vs 12.0 mos (HR 0.56)
- ORR 58% vs 32%
- Fewer G3-4 TRAEs & discontinuations
- New preferred G12C option?

2/5

[Oncology Brothers @OncBrothers]

2. SAFFRON: PhIII Osimertinib + savolitinib vs plat-pem in EGFRm/MET-high NSCLC post-osi (n=338):

- mPFS 7.6 vs 5.4mos (HR 0.55)
- mOS 17.8 vs 12.9mos (HR 0.68)
- All-oral, OS benefit in MET-driven resistance after Osi.

3/5

[Oncology Brothers @OncBrothers]

Day 3 (Presidential II) #ESMO26 highlights:

1. Krascendo-1: Divarasib in KRAS G12C NSCLC

2. SAFFRON: Osi + Savolitinib in EGFRm/MET+ NSCLC

3. CLARITY-Gastric01: Sone-Ve CLDN18.2 ADC in Gastric

4. HARMONi-GI1: Ivo + Chemo in 1L BTC

1/5

#OncTwitter #lcsm #gism @myESMO

[Dr. Cathy Eng @CathyEngMD]

Interim analysis of HARMONi-GI1 phase III findings of #Ivonescimab (bispecific Ab for PD-1/VEGF) + chemo vs. durvalumab + chemo for treatment-naive #biliarytract #cancer (N=682). 👏👏
🔹Primary endpoint: OS of 14.9M vs. 12.1 (HR = 0.75)
🔹PFS: 8.4 vs. 5.8M; HR = 0.61
🔹ORR = 53.8% vs. 32.5%
🔹Subsequent therapies was 31.8% vs. 45.9% (more so in control arm)
@curecc #cancer #cancerresearch @OncoAlert @SMMT_TX

[Dr. Cathy Eng @CathyEngMD]

CLARITY- Gastric 01 (CG-01) Phase III AZD-0901 (Sone-Ve) in 2L+ met #Claudin 18.2 (+) in #Gastroesophageal #cancer vs. investigators choice (N=594)
Primary endpoints: PFS + OS
🔹OS: 10M vs. 5M (HR = 0.47) 👏
🔹12M OS: 38.1% vs. 18.1%, HR = 0.47 (3rd line)
🔹 12M 42.6% in 2nd line
🔹 ORR: 23.3% vs. 13.8%
🔹PFS: HR = 0.77 was NS in 2L+
🔹PFS: HR = 4.1 vs. 2.7M; HR = 0.56 in 3L+

🔹Need more data in the 2L setting; largest benefit seen in 3L+ setting
#ESMO2026 @OncoAlert #cancerresearch @AstraZeneca

[OncUpdates @OncUpdates]

🚨 #ESMO26 Presidential 2 | HARMONi-GI1 Ph3

Ivonescimab (PD-1/VEGF bispecific) + GemCis vs durvalumab + GemCis as 1L in advanced BTC (n=682; China)
✅ mOS: 14.9 vs 12.1 mo (HR 0.75)
✅ mPFS: 8.4 vs 5.8 mo (HR 0.61)
✅ ORR: 53.8% vs 32.5%
❌new signals
#GIOnc #BTC #OncTwitter

[Alok Khorana, MD @aakonc]

Congrats to the study team, going every other week with Lonsurf is a big QOL win for patients

[OncUpdates @OncUpdates]

🚨 #ESMO26 Presidential 2 | SAFFRON Ph3

Osimertinib + savolitinib vs platinum–pemetrexed in EGFRm MET-OE and/or -AMP advanced #NSCLC post-osimertinib
✅ mPFS: 7.6 vs 5.4 mo
✅ mOS:17.8 vs 12.9 mo
✅ Median DoR: 9.7 vs 5.7 mo
⚠️Grade ≥3 TRAEs:40% vs 52%

#LCSM #EGFR #OncTwitter